"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
| Descriptor ID |
D002316
|
| MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
| Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 2 | 3 |
| 1998 | 2 | 3 | 5 |
| 1999 | 1 | 3 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 0 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 3 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 4 | 2 | 6 |
| 2017 | 2 | 0 | 2 |
| 2019 | 3 | 1 | 4 |
| 2020 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors. JACC Heart Fail. 2024 Jun; 12(6S):S1-S3.
-
Pulse Pressure Response to Inotrope Therapy in Cardiogenic Shock: A Subanalysis of the DOREMI Trial. JACC Heart Fail. 2024 Jun; 12(6):1126-1127.
-
Sex-Based Differences in Hemodynamic Response to Inotropes: A Subanalysis of the DOREMI Trial. JACC Heart Fail. 2023 09; 11(9):1275-1277.
-
Practice Changes at U.S. Transplant Centers After the New Adult Heart Allocation Policy. J Am Coll Cardiol. 2020 06 16; 75(23):2906-2916.
-
Pediatric Acute Myocarditis: Predicting Hemodynamic Compromise at Presentation to Health Care. Hosp Pediatr. 2019 06; 9(6):455-459.
-
Ablation of the calpain-targeted site in cardiac myosin binding protein-C is cardioprotective during ischemia-reperfusion injury. J Mol Cell Cardiol. 2019 04; 129:236-246.
-
Na+,K+-ATPase as a Target for Treatment of Tissue Fibrosis. Curr Med Chem. 2019; 26(3):564-575.
-
Home Inotropes in Patients Supported with Left Ventricular Assist Devices. ASAIO J. 2019 01; 65(1):e7-e11.
-
Transseptal transcatheter mitral valve-in-valve for treatment of severe mitral regurgitation in failed bioprosthesis complicated with cardiogenic shock: Case report and review of the literature. Cardiovasc Revasc Med. 2018 Oct - Nov; 19(7 Pt B):874-878.
-
Trends in the Use of Inotropes to List Adult Heart Transplant Candidates at Status 1A. Circ Heart Fail. 2017 Dec; 10(12).